Circulating miR-148/152 family as potential biomarkers in hepatocellular carcinoma

被引:32
|
作者
Wang, Feng [1 ]
Ying, Houqun [2 ]
He, Bangshun [1 ]
Pan, Yuqin [1 ]
Sun, Huiling [1 ]
Wang, Shukui [1 ]
机构
[1] Nanjing Med Univ, Nanjing Hosp 1, Cent Lab, Nanjing, Jiangsu, Peoples R China
[2] Southeast Univ, Coll Med, Nanjing, Jiangsu, Peoples R China
关键词
Hepatocellular carcinoma; miR-148a; miR-148b; miR-152; Biomarker; MESENCHYMAL TRANSITION; CELL-PROLIFERATION; CANCER; MICRORNAS; SUPPRESSES; EXPRESSION; MIR-152; METASTASIS; APOPTOSIS; DIAGNOSIS;
D O I
10.1007/s13277-015-4340-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aberrant expressions of the miR-148/152 family (miR-148a, miR-148b, and miR-152) have been documented in many tumor tissues, including hepatocellular carcinoma (HCC). However, the expression pattern and clinical significance of circulating miR-148/152 family in HCC remain elusive. In this study, we conducted quantitative real-time polymerase chain reaction (qRT-PCR) to examine the levels of serum miR-148a, miR-148b, and miR-152 in 76 HCC cases, as well as 62 controls with benign liver diseases and 55 healthy volunteers. Our results showed that serum levels of three microRNAs (miRNAs) were significantly decreased in HCC cases than those in benign and healthy controls (all P < 0.05). Moreover, they showed strong correlations with each other in HCC group (r = 0.6716, 0.5381, and 0.7712; all P < 0.001). Receiver operating characteristic (ROC) analysis revealed that the combination of circulating miR-148/152 family had an increased area under the curve (AUC) = 0.940 (95 % confidence interval (CI), 0.886-0.973) with the sensitivity of 96.1 % and the specificity of 91.9 %, which were significantly higher than those of serum alpha-fetoprotein (AFP) and three miRNAs alone in differentiating HCC from benign liver diseases. In addition, serum miR-148a and miR-148b were significantly associated with tumor size (P = 0.011 and 0.037) and tumor-node-metastasis (TNM) stage (P < 0.001 and P = 0.034), yet serum miR-152 was only correlated with TNM stage (P = 0.009). Also, dynamic monitoring three miRNAs can help us predict recurrence or metastasis in HCC cases after surgical resection. Besides, Kaplan-Meier analyses demonstrated that the decreased serum miR-148a (P < 0.001) and miR-152 (P = 0.012) was closely correlated with shorten overall survival of HCC patients. Additionally, Cox regression model further indicated that serum miR-148a was strongly associated with the prognosis of HCC patients. Our study suggests that downregulated circulating miR-148/152 family can provide positive diagnostic value for HCC. Moreover, serum miR-148a might be as independent prognostic factor for HCC patients.
引用
收藏
页码:4945 / 4953
页数:9
相关论文
共 50 条
  • [31] Serum miR-21, miR-26a and miR-101 as potential biomarkers of hepatocellular carcinoma
    Zhuang, Chunbo
    Jiang, Weichao
    Huang, Da
    Xu, Luming
    Yang, Qianqian
    Zheng, Lei
    Wang, Xiaobei
    Hu, Lihua
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2016, 40 (04) : 386 - 396
  • [32] Circulating miR-148b and miR-133a as biomarkers for breast cancer detection
    Shen, Jie
    Hu, Qiang
    Schrauder, Michael
    Yan, Li
    Wang, Dan
    Medico, Leonardo
    Guo, Yuqing
    Yao, Song
    Zhu, Qianqian
    Liu, Biao
    Qin, Maochun
    Beckmann, Matthias W.
    Fasching, Peter A.
    Strick, Reiner
    Johnson, Candace S.
    Ambrosone, Christine B.
    Zhao, Hua
    Liu, Song
    ONCOTARGET, 2014, 5 (14) : 5284 - 5294
  • [33] Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma
    Martina Redova
    Alexandr Poprach
    Jana Nekvindova
    Robert Iliev
    Lenka Radova
    Radek Lakomy
    Marek Svoboda
    Rostislav Vyzula
    Ondrej Slaby
    Journal of Translational Medicine, 10
  • [34] Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma
    Redova, Martina
    Poprach, Alexandr
    Nekvindova, Jana
    Iliev, Robert
    Radova, Lenka
    Lakomy, Radek
    Svoboda, Marek
    Vyzula, Rostislav
    Slaby, Ondrej
    JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
  • [35] Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma
    Hung, Yi-Ping
    Shao, Yu-Yun
    Lee, Jan-Mou
    Hsu, Chiun
    Hsu, Chih-Hung
    Yang, Muh-Hwa
    Chao, Yee
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2021, 84 (02) : 144 - 150
  • [36] Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening
    Yang, Jin-shan
    Li, Bao-jian
    Lu, Hua-wei
    Chen, Yu
    Lu, Chuan
    Zhu, Rui-xia
    Liu, Si-hai
    Yi, Qing-ting
    Li, Jing
    Song, Chun-hui
    TUMOR BIOLOGY, 2015, 36 (04) : 3035 - 3042
  • [37] Role of miR-148a in Hepatitis B Associated Hepatocellular Carcinoma
    Yuan, Ke
    Lian, Zhaorui
    Sun, Bill
    Clayton, Marcia M.
    Ng, Irene O. L.
    Feitelson, Mark A.
    PLOS ONE, 2012, 7 (04):
  • [38] Identification of plasma miR-148a as a noninvasive biomarker for hepatocellular carcinoma
    Han, Juqiang
    Li, Jiarui
    Qian, Yun
    Liu, Wenpeng
    Liang, Jiguang
    Huang, Zhigang
    Wang, Shuai
    Zhao, Caiyan
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2019, 43 (05) : 585 - 593
  • [39] miR-210 and miR-152 as biomarkers in invasive ductal carcinoma by liquid biopsy
    Zuccari, D. A. P. D. C.
    Lopes, B. C.
    Ventura, F. V.
    Oliveira, J. G.
    Braga, C. Z.
    Kato-Junior, E. M.
    Bordin-Junior, N. A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] miR-210 and miR-152 as Biomarkers by Liquid Biopsy in Invasive Ductal Carcinoma
    Lopes, Beatriz C.
    Braga, Cristine Z.
    Ventura, Fabricio V.
    de Oliveira, Jessica G.
    Kato-Junior, Edson M.
    Bordin-Junior, Newton A.
    Zuccari, Debora A. P. C.
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (01): : 1 - 17